Irbesartán Kern Pharma

Irbesartan, the active ingredient in Irbesartán Kern Pharma, is an angiotensin II receptor blocker (ARB) presented as an oral dosage form for oral use. It belongs to the antihypertensive therapeutic class and is indicated for the management of hypertension and diabetic nephropathy in adult patients. By selectively antagonising AT‑1 receptors, it helps lower systemic blood pressure and reduces proteinuria associated with kidney disease.

GNH USA supplies Irbesartán Kern Pharma as a licensed, GDP‑compliant product sourced from the EU, providing reliable access to hospitals, pharmacies and clinics worldwide through its international distribution network.

Irbesartan is used to treat conditions related to the renin‑angiotensin system and kidney disease.

Hypertension: lowers elevated blood pressure and helps prevent cardiovascular complications associated with sustained hypertension. Diabetic nephropathy: slows the progression of renal impairment and reduces urinary protein excretion in patients with type 2 diabetes. Proteinuria: decreases abnormal protein loss in the urine by blocking angiotensin II‑mediated renal effects.

Irbesartan may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Headache, often mild and transient. - Fatigue or general weakness. - Upper respiratory tract infection symptoms such as nasal congestion.

Serious or Rare Side Effects: - Angioedema, presenting as swelling of the face, lips, tongue or throat. - Hyperkalemia, indicated by elevated serum potassium levels. - Acute renal failure or a sudden decline in kidney function.

When prescribing Irbesartan, clinicians should consider several precautionary measures to ensure safe use. - Monitor blood pressure: adjust therapy if target levels are not achieved. - Assess renal function: check serum creatinine and eGFR before and during treatment. - Check serum potassium: avoid hyperkalemia, especially when combined with potassium‑sparing agents. - Avoid use in patients with bilateral renal artery stenosis due to risk of renal insufficiency. - Use caution in hepatic impairment as metabolism may be altered. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Irbesartan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Co‑administration with aliskiren in patients with diabetes, which may increase the risk of renal impairment. - Concomitant use of potent CYP3A4 inhibitors (e.g., ketoconazole) that can raise irbesartan plasma concentrations.

Moderate Interactions (Monitor Closely): - Potassium‑sparing diuretics or supplements may elevate serum potassium levels. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) can attenuate the antihypertensive effect. - Concurrent ACE inhibitors may increase the likelihood of hyperkalemia and renal dysfunction.